Allogeneic bone marrow transplantation from unrelated human T-Cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: Retrospective analysis of data from the japan marrow donor program
Allogeneic bone marrow transplantation from unrelated human T-Cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: Retrospective analysis of data from the japan marrow donor program
复制标题
DOI：
10.1016/j.bbmt.2006.09.002
复制
发表时间：
2007-01-01
影响因子：
4.3
通讯作者：
Harada, Mine
中科院分区：
文献类型：
--
作者：
Kato, Koji;Kanda, Yoshinobu;Harada, Mine
来自 HLA 匹配的相关供体的同种异体造血干细胞移植 (allo-HSCT) 被认为可以改善成人 T 细胞白血病/淋巴瘤 (ATLL) 的不良预后。然而，输注来自 HTLV-I 阳性相关供体的 HTLV-I 感染细胞可能会导致在免疫抑制条件下发生供体来源的 ATLL。尽管大多数 ATLL 患者缺乏合适的 HLA 匹配的相关供体并需要 HTLV-I 阴性的无关供体，但目前关于 ATLL 无关骨髓移植 (UBMT) 的结果的信息很少。为了评估 UBMT 在治疗 ATLL 中的作用，我们回顾性分析了通过日本骨髓捐赠计划 (JMDP) 接受 UBMT 治疗的 33 例 ATLL 患者的数据。 UBMT后1年的总生存率(OS)、无进展生存率、疾病进展累积发生率和无进展死亡率分别为49.5%、49.2%、18.6%和32.3%。多变量分析确定受者年龄是 OS 的独立预后因素 (P = .044)。移植时未出现缓解的年龄≥ 50 岁的患者往往具有较高的治疗相关死亡率。我们的观察表明，UBMT 可能是 ATLL 患者的一种可行的治疗选择，并值得根据这些风险因素进行进一步研究。 (C) 2007 年美国血液和骨髓移植协会。
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at I year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age >= 50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors. (C) 2007 American Society for Blood and Marrow Transplantation.